Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia.
We studied 15 hyperprolactinemic women to evaluate possible modifications of bone mineral content after pharmacological treatment. Patients received a dopamine agonist (bromocriptine) for six months after which there was a significant decrease of prolactin plasma levels (P less than 0.01) and a significant increase of bone mineral content (P less than 0.05).
D000293:Adolescent; D000328:Adult; D001842:Bone and Bones / Q000378:metabolism*; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D005542:Forearm; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism*; D013997:Time Factors
D008903:Minerals; D001971:Bromocriptine